EGFR and cancer: Moreover, it is hypothesized that altered glycosylation enables cancer MUC1 to function as a ligand for cell adhesion molecules such as selectins, epidermal growth factor receptor (EGFR), intercellular adhesion molecule-1 (ICAMs), and ECM components, aiding adherence of MUC1-expressing circulating tumor cells to endothelial cells and seeding at isolated sites that settle secondary tumors.